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Abstract Male mice were fed 40 ppm melatonin for
2 months prior to sacrifice at age 26 months, and com-
pared with both 26 and 4 month-old untreated controls. The
nuclear translocation of NF-jB increased with age in both
brain and spleen and this was reversed by melatonin only in
brain. Another transcription factor, AP-1 was increased with
age in the spleen and not in brain and this could be blocked
by melatonin treatment. The fraction of the active relative to
the inactive form of several enabling kinases was compared.
The proportion of activated ERK was elevated with age in
brain and spleen but this change was unresponsive to mel-
atonin. A similar age-related increase in glial fibrillary
acidic protein (GFAP) was also refractory to melatonin
treatment. The cerebral melatonin M1 receptor decreased
with age in brain but increased in spleen. The potentially
beneficial nature of melatonin for the preservation of brain
function with aging was suggested by the finding that an age-
related decline in cortical synaptophysin levels was pre-
vented by dietary melatonin.
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Introduction
The aging brain is characterized by a shift in the homeostatic
balance of inflammatory mediators to a proinflammatory
state. Increased neuroinflammation is marked by higher
steady-state levels of inflammatory cytokines and decreases
in anti-inflammatory molecules [1]. Such elevated inflam-
matory responses in the brain, can lead to increased neuronal
death [2–4]. Several innate immune molecules which can
have a neuroprotective scavenging role in promoting
clearance of pathogens, toxic cell debris and apoptic cells,
can also express neurocytotoxic activity. An appropriate
modulation of innate immune activity by exogenous agents
may limit hyperinflammatory processes while sparing host
defense and repair mechanisms [5]. We have previously
shown that during senescence, there is a selective increase in
mRNA levels of many genes associated with immune
function. Such genes include those for several inflammatory
cytokines. These age-related increases can be attenuated or
even reversed by extended treatment with dietary melatonin
[6–10]. The elevated expression of these genes provoked by
a systemic injection of lipopolysaccharide (LPS) is also
exacerbated in aged animals and the response to this exog-
enous inflammatory stimulus is also diminished by prior
treatment of aged mice with melatonin [6, 11]. The current
study sought to extend this work by examination of some
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proteins of the signaling pathways associated with the
inflammatory cascade. The findings suggest that the effect of
melatonin on transcription of a distinctive set of genes may
be further reflected by parallel changes in translational
events and in the regulation of gene expression by specific
transcription factors. The spleen was also studied as it is an
important non-neural immune regulator. It also showed both
age related changes in transcription factor activity, that were
attenuated by melatonin but the response profile differed
significantly from that of the brain.
Methods
Animal Treatment
Male B6C3F1 mice, a hybrid between C57BL/6 and C3H
from Harlan Labs (Indianapolis, IN), aged 5.5 months
(young group) and 23.4 months (old group), were housed
two to four per cage and were maintained on a 12 h light/
dark cycle in a temperature controlled (22 ± 1C) room.
The B6C3F1 hybrid was used in order to take advantage of
both the genetic and phenotypic uniformity and the vigor
(increased disease resistance, better survival under stress
and greater natural longevity) typical of hybrids, while
maintaining genetic similarity to the published C57BL/6
mouse genome sequence [12]. Food and water were pro-
vided ad libitum. Young (YC) and old (OC) control ani-
mals were fed a pelleted minimal basal diet (AIN-93 M,
Dyets #100900, Dyets Inc., Bethlehem, PA) consisting of
10% sucrose and 14% casein (w/w) as well as a minimal
salt and vitamin mix. The basal diet of two similarly aged
cohorts (YM and OM, respectively) was supplemented
with 40-ppm (w/w) melatonin (Sigma, St. Louis, MO) for
9.3 weeks. All experiments were approved by the Institu-
tional Animal Care and Use Committee at the University of
California, Irvine, and conformed to the National Institute
of Health guide for the care and use of laboratory animals.
Preparation of Samples
Cytoplasmic and nuclear fractions were prepared using the
method of Lahiri and Ge [13]. The brain tissue from each
animal was weighed and homogenized in an ice-cold buffer
(10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA,
0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF and 0.5%
NP-40). The samples were incubated for 10 min and cen-
trifuged (1,5009g) at 4C for 1 min. The supernatant
containing the cytoplasmic constituents was collected and
protease inhibitor cocktail was added. The samples were
aliquoted and stored at -80C. The nuclear pellet was
resuspended in a buffer composed of: 20 mM HEPES pH
7.9, 400 mM NaCl, 1 mM DTT, 1 mM EDTA, 1 mM
EGTA and 1 mM PMSF. The samples were then centri-
fuged at 11,0009g for 5 min at 4C. The supernatant
that contained nuclear extract was aliquoted and stored at
-80C.
Electrophoretic Mobility Shift Assay
The extent of NF-jB and AP-1 activation was determined
in the nuclear fraction of brain tissue using a protocol
developed by Promega (Madison WI). The amount of
protein in 2 ll of the nuclear extract was determined by the
BCA protein assay kit (Pierce, Rockford, IL) and 50 lg of
each sample, incubated with 32P-labeled oligonucleotides
containing either the NF-jB or the AP-1 consensus
sequence, was loaded onto a gel. A negative control con-
taining no cell extract, as well as competitor reactions were
included. The specific competitor contained unlabelled NF-
jB or AP-1 consensus nucleotide while the nonspecific
competitor contained unlabelled SP-1 consensus oligonu-
cleotide. The competitor reactions also contained 50 lg of
nuclear fraction derived from Al-treated mouse brains. This
treatment has been shown not to alter the extent of NF-kB
or AP-1 activation [14]. X-ray films were manually
developed and the intensity of each band was measured and
quantitated using the image analyzer, Eagle Eye, from
Strategene (San Diego, CA).
Western Blots
The levels of ERK, pERK, JNK, pJNK, p38 and pp38 and
the melatonin M1 receptor were determined using Western
blotting. Protein content was determined using the BCA
protein assay kit (Pierce, Rockford, IL). 25 lg of each
sample was resolved on a SDS-10% PAGE and transferred
onto a nitrocellulose membrane (Biorad, Hercules, CA).
After blocking overnight in TBST (20 mM Tris–HCl,
150 mM NaCl and 0.1% Tween 20) containing 5% nonfat
milk, membranes were washed 49 and incubated for 1 h
with primary antibodies (mouse monoclonal antibody
against pERK (1:500); rabbit polyclonal antibody against
ERK (1:1500); goat polyclonal antibody against pJNK
(1:500); rabbit polyclonal antibody against JNK-1 (1:500);
rabbit polyclonal antibody against p38(1:500); and rabbit
polyclonal antibody against p-p38 (1:500), rabbit poly-
clonal antibody against melatonin 1A/B receptors (1:4000)
all purchased from Santa Cruz Biotechnology, Inc., Santa
Cruz, California. After washing the membranes 49 with
TBST, they were incubated with appropriate secondary
HRP-conjugated antibodies (1:10,000). Bands were detec-
ted with ECL reagents (Amersham Pharmacia Biotech,
Piscataway, NJ) following the manufacturer’s protocol. An
antibody against actin (mouse monoclonal, 1:1500 dilu-
tion) purchased from Chemicon International (Temecula,
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CA) was used as an internal control to insure equal loading
of protein for each sample. The intensity of specific bands
was measured and quantitated using the image analyzer,
Eagle Eye, from Strategene (San Diego, CA).
Immunohistochemistry
Immunohistochemistry was performed on paraffin embed-
ded sections. Sections were immersed in antigen unmask-
ing solution (Vector Laboratories, Burlingame, CA) for
20 min at 80C in a water bath. Endogenous peroxidase in
tissue was blocked by treating with 3% H2O2 in PBS for
20 min at room temperature. Nonspecific background
staining was blocked by a 2 h incubation in 2% bovine
serum albumin with 0.3% Triton X-100. Sections were then
incubated with primary antibody (synaptophysin 1:1000,
Santa Cruz, CA) overnight at 4C, then rinsed in PBS with
0.1%Triton-X100 and incubated for 1 h at room tempera-
ture with biotinylated secondary antibody using an avidin
DH and biotinylated enzyme complex kit (Vector Labo-
ratories, Burlingame, CA). Finally, the sections were
incubated for 4 min with diaminobenzidine (Vector Lab-
oratories, Burlingame, CA). Sections were further pro-
cessed by dehydration in a series of graded ethanol, cleared
with xylene, and then coverslipped with 1,3-diethyl-8-
phenylxanthine (DPX). Control sections were incubated in
parallel without primary antibody and these sections failed
to develop specific staining. Immunostaining was observed
under a Nikon Eclipse 80i microscope mounted with a
Nikon DS high-resolution digital color camera
(1,280 9 1,024 pixel). Image acquisition and analysis was
performed using NIS-Elements AR version 3.0 software.
Digital images were analyzed using the Ver.3.00 analysis
program (Nikon, Melville, NY). The percentage of
immunostained area was quantitated by averaging several
images per section. All experiments were repeated at least
twice, with n = 6–8 animals per group. All quantitative
comparisons were performed on sections processed at the
same time.
Statistical Analysis
The differences among these groups were tested using one-
way analysis of variance followed by the Tukey test.
Values were accepted as significant if P \ 0.05 level, using
a two-tailed criterion.
Results
Treatment of mice with melatonin in the diet did not alter
rates of food consumption or accretion of body weight in
either young or old mice. Electrophoretic mobility shift
analysis (EMSA) revealed that the level of active tran-
scription factor NF-jB, which is associated with associated
with inflammatory responses, was elevated in both brain
and spleen with age. Treatment with melatonin reduced the
activity of this factor in brains of both young and old
animals (Fig. 1a). In the spleen there was a larger age-
related increase in active NF-jB but this was not changed
by dietary melatonin (Fig. 1b).
Active AP-1, which is related to immune activation, was
also increased with age in the spleen Fig. 2a and this ele-
vation was prevented by melatonin treatment. However, in
the brain, no corresponding changes of AP-1 with age or
melatonin treatment were found (Fig. 2b).
In order to gain insight into the regulation of these
transcription factors, the fraction of several kinases present
in the phosphorylated form was compared to the amount
present as the inactive unphosphorylated form. In both
cortical tissue (Fig. 3a) and spleen (Fig. 3b), the ratio of
pERK/ERK was elevated with age, and this was unaltered
by prior melatonin treatment. Neither pJNK/JNK nor pp38/
p38 ratios were significantly altered with age in either brain
or spleen (data not shown). However, in the spleen, dietary
0
100
200
300
400
500
YC YM OC OM
N
F-
kB
 a
ct
iv
ity
 (d
en
sit
om
eti
c u
nit
s) 
N
F-
kB
 a
ct
iv
ity
 (d
en
sit
om
eti
c u
nit
s) 
0
50
100
150
200
250
300
350
YC YM OC OM
*
a
b
Fig. 1 Effect of melatonin on levels of activation of NF-kB in a
cortex and b spleen of 4.5 and 26.5 month-old mice as determined by
EMSA. n = 8 for each group. * = Differs from value for untreated
control (P \ 0.05)
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melatonin depressed pJNK/JNK values in both young and
aged mice (Fig. 4).
Melatonin M1 receptor density in brain was reduced
with age (Fig. 5a), while in the spleen, the melatonin
receptor content increased with age (Fig. 5b). Neither of
these changes were altered by melatonin.
The proportion of astrocytes expressing GFAP can be
considered as a marker of brain immune activation. In
accord with several prior reports, GFAP levels were
increased with age. However, melatonin treatment did not
alter this (Fig. 6). Synaptic nerve endings were visualized
using immunohistochemical procedures for synaptophysin
and staining intensity was quantitated. Synaptophysin
density was reduced in cortex with aging and this was
completely reversed by the melatonin treatment (Fig. 7a, b).
Discussion
Using gene expression analysis as a tool, we have previ-
ously reported a general age-related increase in unpro-
voked basal levels of inflammation for mouse brain [6].
With senescence, the levels of mRNAs of several inflam-
matory cytokines and other indices of inflammation are
elevated and the responses to an exogenous stimulus
(lipopolysaccharide, LPS) can be exaggerated and pro-
longed [8]. Many of these changes are partially or com-
pletely reversed following extended exposure to dietary
melatonin [9]. While changes in gene expression have been
demonstrated previously, transcriptional activity does not
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Fig. 2 Effect of melatonin on levels of activation of AP-1 in a cortex
and b spleen of 4.5 and 26.5 month-old mice. n = 8 for each group as
determined by EMSA. * = Differs from value for untreated control
(P \ 0.05)
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Fig. 3 Effect of melatonin on levels of activation of ERK in a cortex
and b spleen of 4.5 and 26.5 month-old mice as determined by
Western blot. n = 7–8 for each group. * = Differs from value for
untreated control (P \ 0.05)
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Fig. 4 Effect of melatonin on levels of activation of JNK in spleen of
4.5 and 26.5 month-old mice. n = 7–8 for each group mice as
determined by Western blot. * = Differs from value for untreated
control (P \ 0.05)
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always correlate directly with activity of the protein
product. The current study has investigated changes in
activation levels of proteins involved in the inflammatory
cascade. In parallel with findings from quantitative gene
expression, evidence of elevated inflammation with age
also derives from the current studies on transcription fac-
tors associated with inflammation. NF-jB was increasingly
activated with age in cerebral cortex and spleen despite the
absence of an exogenous stimulus. In nervous tissue, NF-
jB is not merely a pro-inflammatory species but also has
an important role in regulation of neurogenesis and short-
term spatial memory [15] and in neuroprotection from
stressors [16]. Neurogenesis, memory and intrinsic neuro-
protective mechanisms are all increasingly impaired with
age, in parallel with increased pro-inflammatory NF-jB. It
therefore seems plausible that reversal of the age-related
elevation of NF-jB could have a restorative effect on these
cognitive and cellular processes. Indeed, our results suggest
that melatonin can reduce NF-jB in the cortex of both
young and aged animals.
However, since none of these events are improved with
age, inhibition of an age-related elevation of NF-kB is
likely to be beneficial rather than detrimental. In the case of
brain, this increase was prevented by dietary melatonin.
The transcription factor AP-1 has recently been identi-
fied as an upstream regulator of several pro-inflammatory
genes that may be involved in Alzheimer’s disease (AD),
which is primarily an age-related memory disorder [17].
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Fig. 5 Effect of melatonin on melatonin receptor content in a cortex
and b spleen of 4.5 and 26.5 month-old mice as determined by
Western blot. n = 7–8 for each group. * = Differs from value for
untreated control (P \ 0.05)
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Fig. 6 Effect of melatonin on GFAP levels in cortex of 4.5 and
26.5 month-old mice as determined by Western blot. n = 8 for each
group. * = Differs from value for untreated control (P \ 0.05)
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Fig. 7 Immunohistochemical staining (a) together with quantitation
(b) for synaptophysin in cortex of 4.5 and 26.5 month-old mice.
Some animals of each group were treated with dietary melatonin.
A = Young controls, B = Young ? melatonin, C = Aged, D =
Aged ? melatonin. n = 7–10 for each group. * = Differs from value
for untreated control (P \ 0.05)
Neurochem Res (2010) 35:2035–2042 2039
123
Nevertheless, in this study AP-1 activation in brain was
unchanged with age and unaffected by melatonin treat-
ment. In the spleen, levels of AP-1 rose with age and this
increase was prevented by dietary melatonin. Thus, the
responses of these two tissues to aging and to melatonin
treatment, broadly resembled each other but differed in
details.
When the degree of activation of several key kinases
was quantitated, ERK was increased in aged brain but was
reduced in aged spleen, Neither of these responses was
altered by melatonin. The proportion of JNK and p38 that
were activated by phosphorylation were unaltered with age.
However, melatonin depressed activation of JNK in aged
spleen but not brain. An age-related reduction in splenic
ERK and JNK activation has been previously described and
related to diminished lymphoproliferation in aged animals
[18]. These results imply that melatonin treatment may
modulate kinase activity in both a tissue-specific and
pathway-specific manner. Further elucidation of these
pathways may provide promising new therapeutic targets
for age-related and inflammatory disorders.
GFAP levels were increased with age and this is in
accord with our prior finding that GFAP mRNA expression
is also elevated with age [9]. Not only is GFAP elevated
with age but also its increase in response to brain injury is
accentuated and prolonged. This may contribute to the
worse cognitive outcome encountered following traumatic
brain injury in the elderly [19]. We did not observe an
effect on GFAP levels in melatonin treated animals, sug-
gesting that age-related GFAP changes do not involve
AP-1 or NF-jB signaling.
The overall effects of dietary melatonin upon proteina-
ceous indices of immune activation including transcription
factors and their regulatory kinases, are not always con-
cordant with levels of gene expression. In general the
proteins are much less susceptible to alteration by mela-
tonin that are the corresponding mRNAs. Such a disparity
between mRNA and levels of the corresponding protein is
found with the melatonin receptor. The receptor content is
depressed in the aging brain, but its expression levels are
elevated [9]. This may be due to a variety of regulatory
steps between mRNA synthesis and the elaboration of
protein, including mRNA stability, and siRNA. The lack of
consonance between gene expression and levels of corre-
sponding proteins may also reflect post-translational mod-
ification of proteins and consequent blunting of the changes
occurring in mRNA production. Comparable to the current
findings, an age-related reduction in melatonin receptor
MT1 in the hypothalamic suprachiasmatic nucleus and a
lack of response of levels of this receptor in brain to
melatonin treatment has been described for both senes-
cence-accelerated mice (SAMP8) and senescence-acceler-
ated resistant mice (SAMR1) [20, 21].
The changes in profiles of immune-related transcription
factors with age and their responses to melatonin vary
between brain and spleen but are not always in accord. Since
the spleen plays a major role in systemic immune regulation,
it might be expected respond to aging with a profile differing
from that of the brain, which has only intrinsic immune
activity. What is remarkable is that the melatonin receptor
density is depressed with age in the brain and elevated in the
spleen. This difference cannot clearly be linked to respon-
sivity to melatonin treatment. The age–related increase in
spleen melatonin receptor that we found parallels a similar
increase for the MT1 receptor of thymus, another immune-
active tissue, while the levels of this receptor in all other
tissues studied declined with age [22].
The actions of melatonin do not appear to depend
entirely on melatonin receptor density. A more subtle
dissection of melatonin receptor subtypes may be needed
and this awaits the development of more selective anti-
bodies. While dietary melatonin, is known to elevate
plasma and brain levels of melatonin significantly [23], it
did not alter melatonin receptor density. This may account
for the lack of habituation to, and absence of, withdrawal
effects of melatonin [24] and its analogs [25]. It has been
reported the sensitivity to melatonin is reduced with age in
the suprachiasmantic nucleus [26]. This may reflect
reduction of melatonin receptor density and thus account
for the ability of elevated levels of exogenous melatonin to
reverse age-related changes in nervous tissue.
That the modulation of cortical levels of inflammation
by melatonin may have physiological relevance for the
aged organism, is suggested by the results for synapto-
physin. Age-related losses of this protein have been
reported by others [27] and these are exacerbated in double
transgenic APP751SL/PS1M146L mice overexpressing
both human mutant forms of amyloid precursor protein and
presenilin [28]. These mice over-produce the AD-related
amyloid-b (Ab) peptide, which is known to stimulate
inflammatory signaling [17]. Both the photomicrographs
and the statistical analysis of quantitated immunostaining
demonstrate that the age-related loss of synaptophysin can
be prevented by melatonin treatment. Similarly, acute
melatonin administration can protect against 1,3-bis(2-
chloroethyl)-1-nitrosourea (BCNU)-induced or metham-
phetamine-induced reduction in synaptophysin [29, 30].
Since this protein may be an index of synaptic integrity,
this implies that melatonin may be beneficial in the pres-
ervation of synaptic performance during senescence, and
that melatonin may also have disease-specific application
in the clinic.
The disparate effects of melatonin upon transcription
factors and kinase activation in various tissues may give
clues as to the mechanism of action of this agent. The
original concept that melatonin primarily acts as an anti-
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oxidant has been questioned due to the very low levels of
endogenous tissue melatonin which would be insufficient
to provide marked scavenging of reactive oxygen radicals,
and to the ability of melatonin to act as a pro-oxidant in
isolated systems [10]. More likely is a more primary effect
of melatonin upon the pattern of gene expression of a
specific tissue. This could be enabled by very low levels of
a triggering compound and could account for differing
effects on the mRNA profile of each tissue.
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With Respect This issue is dedicated to honor Professor Abel
Lajtha and a few reminiscences are appropriate. I have known Abel
for 48 years. Even before this I knew of his work, and several of his
papers are cited in my Ph. D. thesis from Birmingham University,
England. This illustrates the lengthy period that Abel has had
worldwide impact. He is unquestionably one of the fathers of modern
neuroscience. His research accomplishments, while very extensive,
are however only part of the overall contributions that he has made to
our discipline. His leadership at first New York State’s Center for
Neurochemistry at Ward’s Island, later at Orangeburg, his founding of
‘‘Neurochemical Research’’ and his editing a multi-volume series
‘‘Handbook of Neurochemistry’’ are all major milestones in the
emergence of Neuroscience as an independent discipline. These
contributions have been continuous and uninterrupted over a large
span of time.
Others may elaborate on exceptional feats. I would like to mention
Abel’s human qualities which are also outstanding and which have
had a very positive effect on many people’s lives. I have always found
Abel to be most sympathetic and to take on other people’s problems
as if they were his. He has been unselfish with his time and courteous
in responding to the needs of his fellows at whatever stage in their
career they are at. Such a positive and generous personality, combined
with his scientific insights goes far to account for his successful
leadership in a wide range of areas. Although we have never
collaborated directly together, several times in my career, Abel has
rescued me from a difficult situation and I will always be grateful for
his unstinting support.
I note that Abel has already 4 publications in 2010 (by May) and I
wish him many more productive and happy years—SCB.
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